Alfred E Mann Foundation For Scientific Research

New project developmentthis program covers (a) the monitoring and evaluation of several early stage advanced research and development efforts underway that are directed at developing - innovative technologies, project ideas and concepts before they progress to the status of full-fledged development programs, and (b) ongoing efforts related to the advancement of commercial development and protection of intellectual property of these projects across the development lifecycle. The team comprises the full range of expertise available at amf, including - executive management, research scientists and engineers, legal and intellectual property experts, business development strategists and analysts.expenses may include ongoing participation in the development effort including research and development support, collaboration management, conference and professional society meeting attendance, service in management or on the board of directors of spinout entities, patent prosecution and the prosecution of infringement actions to protect the value of the intellectual property we create. In addition to payroll expenses and direct expenses paid to outside vendors for goods and services related to projects, expenses in this program may include travel expenses, patent prosecution expenses and fees, legal fees (for internal and outside legal counsel) for expenses to create, preserve and protect intellectual property from infringement and remedy past infringement, and incentive and other compensation payments to employees and others related to these programs and actions. In some cases, certain of these expenditures might be incurred long after the projects have been launched into spinout companies or licensed to third parties.revenues associated with these projects (some of which may accrue long after the project and any related program have been out-licensed or launched into a spinout company) may include recoveries of judgments or settlements from patent infringement matters, royalties on net sales of licensed products, milestone payments, ongoing contract r&d from partners, licensees and spinout companies, interest, and proceeds of liquidity events (e.g., initial public offerings, acquisitions) involving retained equity interests in projects that have been spun out as startup companies.status:design and development activities are underway for a new bioelectronic program based on the business case analysis conducted in the prior year. These activities included generation of initial system requirements, assembly of a team of key opinion leaders with domain expertise, and the initiation of some fundamental applied research in the area of novel electrode design, including completion of pre-clinical testing. Additionally, the business development team, along with executive management and other staff, performed preliminary due diligence on a number of assets.

Implantable neuromodulation project #1 to treat chronic disease the aim of the amf program is to develop a neurostimulation system that will improve medical outcomes at a lower cost and/or higher patient satisfaction than currently available treatment options. Such a system will consist of a fully implantable neural stimulator for seamless operation and requiring minimal interaction from a patient, with the goal of offering a higher level of patient satisfaction, adoption, and compliance.status:final design verification testing activities of the implantable device and externals are underway in support of a first-in-human study. Design and manufacturing improvements have been made; pre-clinical animal studies were completed.

Implantable neuromodulation project #2: - to treat a range of neurological conditions. The system will consist of an implantable neural stimulator and externals designed to maximize therapy outcomes and patient satisfaction while minimizing system costs.status:planning, design, and development of the first in-human implant and externals is underway; feasibility planning and initiatives include pre-clinical studies and computational modeling of targeted neural structures.

Implantable drug pump (idp)the idp is a sophisticated, highly programmable drug infusion device that is implanted in the body and refilled via a hypodermic needle through the skin. Infusion rates and schedules may be programmed, and via various forms of catheters, drugs can be delivered intrathecally to the spinal column, into the abdomen, into the brain, or intravenously. Status: amf has sold the idp technology to a strategic partner that is an international medical device company. Amf continues to support the strategic partner as it works to adapt the design for diabetes by delivering insulin to the abdomen and ready it for commercialization for the benefit of patients with hard-to-treat type 1 diabetes. First-in-human implantation has been accomplished.

Implantable neuromodulation project #2 - to treat a range of neurological conditions. The system will consist of an implantable neural stimulator and externals designed to maximize therapy outcomes and patient satisfaction while minimizing system costs.status planning, design, and development of the first-in-human implant and externals is underway; feasibility planning and initiatives include pre-clinical studies and computational modeling of targeted neural structures.

Implantable myoelectric sensor ii (imes infinity)the technology has been licensed to a strategic partner that is an international medical device company.status:additional analysis and development work was done to predict feasibility of the use of the device on lower limbs; design transfer support activities were also conducted.